We have compared the effects of progressive (30% and 60%) in vitro haemodilution with hydroxyethyl starch (HES), gelatin (GEL) and albumin (ALB) with haemodilution using 0.9% saline in 96 patients by thrombelastography. Haemodilution with HES, GEL and ALB significantly (P < 0.05) compromised coagulation time (k), angle alpha and maximal amplitude (MA), with HES having the most negative effect a...

A 16 year old girl with a two year history of systemic sclerosis developed left axillary vein thrombosis. Prolonged euglobulin clot lysis time, anti-endothelial cell antibodies, and raised von Willebrand factor antigen were shown.

Factor XIII (F XIII) is an essential parameter for final clot stability. The purpose of this study was to determine the impact of the addition of factor (F)XIII on clot stability as assessed by Rotation Thromboelastometry (ROTEM®). In 90 intensive care patients ROTEM® measurements were performed after in vitro addition of F XIII 0.32 IU, 0.63 IU, 1.25 IU and compared to diluent controls (DC; aq...

A simple screening method for determining the fibrinolytic activity of plasma is described. A streptokinase activated system is used, which measures the result of the interplay of all components of the fibrinolytic system with the exception of activators, which are added in excess. Mean lysis time and standard deviation with this method is 6.9 +/- 1.4 min. The sensitivity of the method in detec...

Objective: The present study was undertaken to investigate the thrombolytic activity of Punica granatum fruit and peel extract. Methods: Phytoconstituents and free radical scavenging activity of P. granatum extract were performed. Ethanolic and aqueous extract of fruit and peel of the plant was used for in vitro clot lysis activity using streptokinase (SK) as standard. In a series of pre-weighe...

A monoclonal antibody (MoAb) to a -plasmin inhibitor designated JTPI-1 inhibited antiplasmin activity by interfering with formation of a2-plasmin inhibitor (a2-Pl)-plasmin complex. With this MoAb, we observed plasma clot lysis in vitro and evaluated the potential of JTPI-1 to serve as a new therapeutic agent for thrombolysis. After adding lThl labeled fibrinogen to plasma, clots were made by ad...

The increased risk of vascular complications in type 1 diabetes may in part be explained by changes in haemostatic function. In the present study, we investigated the fibrin clot properties in patients with type 1 diabetes in relation to sex and microvascular complications. The study included 236 patients (107 women) aged between 20-70 years and without any history of cardiovascular disease. Fi...

Hemostasis is a process of blood clot formation at the site of vessel injury. When a blood vessel wall breaks, the hemostatic response must be quick, localized, and carefully regulated. Bleeding or a thrombosis may occur due to missing or dysfunctional moieties of the coagulation or fibrinolytic factors. The pathways of thrombin-stimulated fibrin clot formation and plasmin-induced clot lysis ar...

BACKGROUND Previously, we demonstrated that hypofibrinolysis, a decreased capacity to dissolve a blood clot as measured with an overall clot lysis assay, increases the risk of venous thrombosis. Here, we investigated the combined effect of hypofibrinolysis with established risk factors associated with hypercoagulability. METHODS AND FINDINGS Fibrinolytic potential was determined with a plasma...